Manufacturer of Controlled Substances; Notice of Application, 63203 [2010-25849]
Download as PDF
<![CDATA[
jlentini on DSKJ8SOYB1PROD with NOTICES
Federal Register / Vol. 75, No. 198 / Thursday, October 14, 2010 / Notices
CPC and requires CPC to inform EPA of
its choice of compliance option within
30 days from the effective date of the
decree.
Under Option 1, CPC will construct a
new Kiln 6 as authorized by an Arizona
Department of Environmental Quality
permit within a 42-month time period
and permanently shut down kilns 1–4
within six months of commencing
operation of Kiln 6.
Under Option 2, CPC will continue to
operate Kilns 1 through 4 but will
install Particulate Matter controls
(enclosures, spraybars and upgrades to
existing baghouses) and accept more
stringent limits than those already in the
permit on equipment previously
modified. Option 2 requires stricter
opacity standards for some limestone
storage piles, mill feed hoppers, and
mill rejects bins. Option 2 also imposes
lower emission limits on various
baghouses and dust collectors and
requires the installation of a bag leak
detection system.
Option 2 also requires CPC to install
software to optimize the operation of the
existing kilns, which EPA expects will
lead to reduced fuel use and reduced
combustion emissions.
The Department of Justice will receive
for a period of thirty (30) days from the
date of this publication comments
relating to the proposed Consent Decree.
Comments should be addressed to the
Assistant Attorney General,
Environment and Natural Resources
Division, and either e-mailed to
pubcomment-ees.enrd@usdoj.gov or
mailed to P.O. Box 7611, U.S.
Department of Justice, Washington, DC
20044–7611, and should refer to United
States v. CalPortland Company, No.
4:10–CV–00573–DCB and DOJ No. 90–
5–2–1–08306.
The Consent Decree may be examined
at the Office of the United States
Attorney for the District of Arizona, 405
W. Congress Street, Suite 4800, Tucson,
AZ 85701–5040. During the public
comment period, the Consent Decree
may also be examined on the following
Department of Justice Web site: https://
www.usdoj.gov/enrd/
Consent_Decrees.html. A copy of the
Consent Decree may also be obtained by
mail from the Consent Decree Library,
P.O. Box 7611, U.S. Department of
Justice, Washington, DC 20044–7611, or
by faxing or e-mailing a request to Tonia
Fleetwood, tonia.fleetwood@usdoj.gov,
Fax No. (202) 514–0097, phone
confirmation number (202) 514–1547. In
requesting a copy from the Consent
Decree Library, please enclose a check
in the amount of $11.25 (25 cents per
VerDate Mar<15>2010
16:30 Oct 13, 2010
Jkt 223001
page reproduction cost) payable to the
U.S. Treasury.
Maureen Katz,
Assistant Section Chief, Environmental
Enforcement Section, Environment and
Natural Resources Division.
[FR Doc. 2010–25876 Filed 10–13–10; 8:45 am]
BILLING CODE 4410–15–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on January 28, 2010,
PCAS–Nanosyn, LLC, 3331–B Industrial
Drive, Santa Rosa, California 95403,
made application to the Drug
Enforcement Administration (DEA) as a
bulk manufacturer of the basic classes of
controlled substances listed in schedule
II:
Drug
Schedule
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Phencyclidine (7471) ....................
Codeine (9050) .............................
Diprenorphine (9058) ...................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Methadone (9250) ........................
Morphine (9300) ...........................
Oxymorphone (9652) ...................
Fentanyl (9801) ............................
II
II
II
II
II
II
II
II
II
II
II
II
II
The company is a contract
manufacturer. At the request of the
company’s customers, it manufactures
derivatives of controlled substances in
bulk form only. The primary service
provided by the company to its
customers is the development of the
process of manufacturing the derivative.
As part of its service to its customers,
the company distributes the derivatives
of the controlled substances it
manufactures to those customers. The
company’s customers use the newlycreated processes and the manufactured
derivatives in furtherance of
formulation processes and dosage form
manufacturing; pre-clinical studies,
including toxicological studies; clinical
studies supporting investigational Drug
Applications; and use in stability
studies.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR § 1301.33(a).
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
63203
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than December 13, 2010.
Dated: October 6, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–25849 Filed 10–13–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Occupational Safety and Health
Administration
[Docket No. OSHA–2010–0044]
Advisory Committee on Construction
Safety and Health (ACCSH); Notice of
Reestablishment of Charter
Occupational Safety and Health
Administration (OSHA), Labor.
ACTION: Notice of reestablishment of the
ACCSH Charter.
AGENCY:
The Secretary of Labor has
reestablished the Charter of the
Advisory Committee on Construction
Safety and Health (ACCSH) for two
years.
FOR FURTHER INFORMATION CONTACT: Mr.
Francis Dougherty, Office of
Construction Services, Directorate of
Construction, Occupational Safety and
Health Administration, Room N–3468,
U.S. Department of Labor, 200
Constitution Avenue, NW., Washington,
DC 20210; telephone (202) 693–2020
(TTY (877) 889–5627).
SUPPLEMENTARY INFORMATION: In
accordance with the Federal Advisory
Committee Act (FACA), as amended
(5 U.S.C. App. 2), and its implementing
regulations (41 CFR 102–3 et seq.), the
Secretary of Labor (Secretary) is
reestablishing the ACCSH Charter for
two years. The Charter will be dated,
signed, and filed on October 29, 2010
and will expire two years from the date
filed.
ACCSH is a continuing advisory
committee established under Section
107 of the Contract Work Hours and
Safety Standards Act (Construction
Safety Act (CSA))(40 U.S.C. 3704(d)(4)),
to advise the Secretary and the Assistant
Secretary of Labor for Occupational
Safety and Health in the formulation of
construction safety and health standards
as well as on policy matters arising
under the CSA and the Occupational
SUMMARY:
E:\FR\FM\14OCN1.SGM
14OCN1
]]>Agencies
[Federal Register Volume 75, Number 198 (Thursday, October 14, 2010)]
[Notices]
[Page 63203]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-25849]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on January 28, 2010, PCAS-
Nanosyn, LLC, 3331-B Industrial Drive, Santa Rosa, California 95403,
made application to the Drug Enforcement Administration (DEA) as a bulk
manufacturer of the basic classes of controlled substances listed in
schedule II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Methylphenidate (1724)..................... II
Phencyclidine (7471)....................... II
Codeine (9050)............................. II
Diprenorphine (9058)....................... II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Hydrocodone (9193)......................... II
Methadone (9250)........................... II
Morphine (9300)............................ II
Oxymorphone (9652)......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company is a contract manufacturer. At the request of the
company's customers, it manufactures derivatives of controlled
substances in bulk form only. The primary service provided by the
company to its customers is the development of the process of
manufacturing the derivative. As part of its service to its customers,
the company distributes the derivatives of the controlled substances it
manufactures to those customers. The company's customers use the newly-
created processes and the manufactured derivatives in furtherance of
formulation processes and dosage form manufacturing; pre-clinical
studies, including toxicological studies; clinical studies supporting
investigational Drug Applications; and use in stability studies.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR Sec. 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than December 13, 2010.
Dated: October 6, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2010-25849 Filed 10-13-10; 8:45 am]
BILLING CODE 4410-09-P
